Search
obinutuzumab (Gazyva)
Indications:
- treatment-naive patients with chronic lymphocytic leukemia
- for use with chlorambucil
- 1st line treatment of follicular lymphoma [2]
- lupus nephritis: for use with mycophenolate & glucocorticoid [4]
Adverse effects:
- infusion-related reactions
- neutropenia
- thrombocytopenia
- anemia
- musculoskeletal pain, mylagias, bone pain
- fever
- nausea [2]
- associated with severe COVID-19 infection [3]
- boxed warning
- potential risks for hepatitis B virus reactivation & progressive multifocal leukoencephalopathy
Mechanism of action:
- humanized type II anti-CD20 monoclonal antibody
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- FDA News Release: Nov. 1, 2013
FDA approves Gazyva for chronic lymphocytic leukemia
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm
- Marcus R, Davies A, Ando K et al
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
N Engl J Med 2017; 377:1331-1344. October 5, 2017
PMID: 28976863
http://www.nejm.org/doi/full/10.1056/NEJMoa1614598
- Ingram I
Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients -
Plus: Active chemo treatment may not be a COVID risk factor.
MedPage Today February 5, 2021
https://www.medpagetoday.com/hematologyoncology/lymphoma/91092
- Monaco K
Obinutuzumab for Lupus Nephritis Boosts Complete Remissions.
Positive phase III data being shared with FDA.
MedPage Today. February 7, 2025
https://www.medpagetoday.com/rheumatology/lupus/114139
- Furie RA et al
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
N Engl J Med. 2025. Feb 7.
Not yet indexed in PubMed
https://www.nejm.org/doi/full/10.1056/NEJMoa2410965